News Sentiment

ZYME sentiment intelligence

Zymeworks Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 24.19 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 8

high-authority source matches

Trend context Trend active

-6.5% over one week, +4.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -6.5% Price reacting lower
Trend fit Trend active 4.5% over four weeks
Fair value 66.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 30
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 8
Barron's 3
simplywall.st 3
Quiver Quantitative 2
MarketBeat 2
Seeking Alpha 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 24
Deals and strategy 10
Analyst action 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Insider Monkey Direct company coverage

Zymeworks Inc. (NASDAQ:ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (NASDAQ: ZYME) held its Q1 2026 earnings call, reporting an EPS miss of $-0.59 against an expectation of $-0.1. The company highlighted significant upcoming milestones, including the PDUFA date for zanatumab in first-line GEA, anticipating milestone payments from J

Tone
Positive 63/100
Event
Earnings
Published
08 May 2026 12:10
Source
Insider Monkey
Stock Titan Direct company coverage

Zymeworks (NASDAQ: ZYME) monetizes Ziihera royalties and boosts cash above $400M

Zymeworks reported a Q1 2026 net loss of $44.2 million, wider than the previous year, with collaboration revenue falling significantly to $2.4 million due to fewer milestone payments. However, the company boosted its cash, cash equivalents, and marketable securities to over $400

Tone
Positive 61/100
Event
Earnings
Published
07 May 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Zymeworks makes two interim leaders permanent to steer pipeline and deals

Zymeworks has appointed Dr. Adam Schayowitz as Executive VP & Head of R&D and Scott Platshon as Executive VP & Chief Business Officer, making their interim roles permanent. These appointments aim to strengthen the company's R&D, advance its clinical pipeline, and manage its portf

Tone
Positive 70/100
Event
Market update
Published
09 Apr 2026 01:09
Source
Stock Titan
GlobeNewswire Direct company coverage

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks Inc. reported its financial results for the fourth quarter and full year 2025, highlighting a strategic shift towards predictable revenue streams and disciplined capital allocation. The company announced significant progress with its partnered programs, including regula

Tone
Positive 74/100
Event
Earnings
Published
06 Mar 2026 20:10
Source
GlobeNewswire
Stock Titan Direct company coverage

Zymeworks (NASDAQ: ZYME) posts 39% 2025 revenue growth, narrows loss

Zymeworks reported a significant financial improvement in 2025, with total revenue rising 39% to $106.0 million and its net loss narrowing by 34% to $81.1 million. The company ended the year with strong liquidity, holding $270.6 million in cash and short-term investments, further

Tone
Positive 72/100
Event
Balance sheet
Published
06 Mar 2026 16:39
Source
Stock Titan
Insider Monkey Direct company coverage

Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript

Zymeworks Inc. discussed its Q4 2025 earnings and provided updates on its clinical programs and strategic financing. Key highlights include positive Phase III results for zanidatumab in HER2-positive GEA, a new $250 million royalty-backed note financing with Royalty Pharma to fun

Tone
Positive 75/100
Event
Earnings
Published
03 Mar 2026 12:53
Source
Insider Monkey
Stock Titan Direct company coverage

Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing

Zymeworks Inc. has secured a $250 million non-recourse royalty-backed note financing agreement with Royalty Pharma. This deal leverages 30% of future Ziihera (zanidatamab-hrii) royalties from Jazz Pharmaceuticals and BeOne Medicines as collateral, providing Zymeworks with non-dil

Tone
Positive 67/100
Event
Deals and strategy
Published
02 Mar 2026 11:29
Source
Stock Titan
Delta Optimist Direct company coverage

Could Zymeworks' blockbuster drug success revive Vancouver biotech scene?

Zymeworks Inc. has achieved a significant breakthrough with its lead cancer drug, Zanidatamab, proving effective in Phase 3 trials, potentially generating billions in sales. This success is poised to invigorate Vancouver's biotech sector by creating jobs, attracting investment, a

Tone
Positive 73/100
Event
Market update
Published
11 Dec 2025 23:09
Source
Delta Optimist
BioSpace Direct company coverage

Jazz, Zymeworks Bispecific Achieves ‘Practice-Changing’ Results in Stomach Cancer Study

Jazz Pharmaceuticals and Zymeworks' HER2 bispecific antibody Ziihera significantly improved progression-free survival in a Phase III study for gastroesophageal adenocarcinoma, paving the way for a regulatory filing in early 2026. Analysts are optimistic about Ziihera's potential

Tone
Positive 70/100
Event
Earnings
Published
18 Nov 2025 12:57
Source
BioSpace
The Globe and Mail Direct company coverage

Zymeworks stock hits four-year high on promising results from digestive cancer trial

Zymeworks Inc. stock reached a four-year high following promising results from a late-stage human efficacy trial for its lead drug, Ziihera, in combination with chemotherapy for advanced metastatic gastroesophageal adenocarcinoma (GEA). The drug demonstrated statistically signifi

Tone
Positive 75/100
Event
Earnings
Published
17 Nov 2025 21:09
Source
The Globe and Mail
ts2.tech Direct company coverage

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks Inc. announced positive topline Phase 3 results for Ziihera (zanidatamab-hrii) in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in progression-free and overall survival. Development partner Jazz Pharmaceuticals plans to file an sBLA in

Tone
Positive 75/100
Event
Earnings
Published
17 Nov 2025 20:08
Source
ts2.tech
Business in Vancouver Direct company coverage

FDA approves cancer drug developed by B.C.'s Zymeworks

The FDA has granted accelerated approval for Ziihera, a new drug for biliary tract cancer developed by Zymeworks Inc. in partnership with Jazz Pharmaceuticals. This approval triggers a $25-million milestone payment to Zymeworks and makes them eligible for over $1 billion in total

Tone
Neutral 50/100
Event
Deals and strategy
Published
24 Oct 2025 02:02
Source
Business in Vancouver